Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma 4Hodgkin Disease 4Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Leukemia 3Hematologic Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Kidney Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomatitis 1Stomach Neoplasms 1

Interventions

ofatumumab 10Rituximab 6ibrutinib 5Cyclophosphamide 5fludarabine phosphate 4Bendamustine Hydrochloride 4fludarabine 3Lenalidomide 3Alemtuzumab 3spebrutinib 2navitoclax 2acalabrutinib 2KW-2478 2venetoclax 1tirabrutinib 1obinutuzumab 1idelalisib 1dinaciclib 1Tablets 1Stem Cell Transplantation 1Rabeprazole 1Pentostatin 1Metronidazole 1Methylprednisolone 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1Lansoprazole 1Itraconazole 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, B-Cell × Diphenhydramine × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡